Virtus ETF Advisers’s Structure Therapeutics GPCR Stock Holding History

Virtus ETF Advisers’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,242	Closed	-$60.8K	–	576
2024 Q4	$60.8K	Buy	2,242 +455	+25%	+$16.1K	0.02%	448
2024 Q3	$78.4K	Buy	1,787 +34	+2%	+$1.31K	0.04%	416
2024 Q2	$68.8K	Buy	1,753 +273	+18%	+$11.2K	0.03%	435
2024 Q1	$63.4K	Sell	1,480 -100	-6%	-$4.22K	0.03%	414
2023 Q4	$64.4K	Sell	1,580 -1,614	-51%	-$92.5K	0.04%	423
2023 Q3	$161K	Sell	3,194 -319	-9%	-$10.3K	0.1%	307
2023 Q2	$146K	Buy	+3,513	New	+$98.4K	0.09%	322

Other funds holding GPCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Virtus ETF Advisers's GPCR Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Structure Therapeutics (GPCR) in Q1 2025, closing a stake of 2,242 shares — an estimated $60.8K sold.

Virtus ETF Advisers first reported a position in GPCR in Q2 2023 and held it in 7 quarters. The position peaked at $161K in Q3 2023. 150 funds tracked by Wall St. Rank hold GPCR as of Q1 2025.

Virtus ETF Advisers reported no remaining Structure Therapeutics position as of Q1 2025 after selling out during the quarter.
Virtus ETF Advisers sold 2,242 Structure Therapeutics shares in Q1 2025, an estimated $60.8K.
Virtus ETF Advisers first reported a position in Structure Therapeutics in Q2 2023 and held it in 7 quarters.
Virtus ETF Advisers's Structure Therapeutics position peaked at $161K in Q3 2023.
150 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.